PTGS2 and Alzheimer disease: Importantly, epidemiological and clinical data suggest that COX-2 inhibitors reduce Alzheimer’s disease risk, and other age-related diseases, notably cancer (Ulrich et al., 2006; Vlad et al., 2008).